Tuesday, January 14, 2025
1/14/2025
PROJECT SUMMARY: Fear regulation is essential for optimal mental health. Maladaptive fear is a hallmark of posttraumatic stress disorder (PTSD), a debilitating condition afflicting 22% of combat veterans. Impaired functioning of infralimbic (IL) prefrontal cortex (PFC) contributes to fear dysregulation in PTSD, however factors contributing to IL deficits are unclear. Not all trauma-exposed individuals develop PTSD, suggesting that predisposition factors may contribute to IL dysfunction and PTSD risk. Elucidating the nature of such factors will help identify novel therapeutics. Growing evidence supports a strong association between severe asthma and PTSD. Mechanisms and cellular substrates whereby severe asthma associated factors regulate PTSD-relevant fear and IL-PFC deficits remain unknown. Using unique mouse paradigms of aeroallergen house dust mite (HDM)-driven inflammation we observe: 1) compromised fear extinction only in mice with allergen-induced Th2/Th17 expansion, an effect dependent on IL-17A and IL-17RA signaling and accompanied by reduced neuronal activation in the IL-PFC; 2) significant upregulation of microglial Il17ra expression in blood-brain-barrier compromised subfornical organ (SFO) inTh2/Th17 mice (but not in SFO non-microglial cells or PFC microglia); 3) IL-17A-induced activation of SFO neurons, and, 4) direct SFO►IL projections that modulate parvalbumin interneurons that regulate IL excitability and fear. Collectively these observations inform our hypothesis: IL-17A engages microglial IL-17RA and SFO-to-IL projections to modulate IL excitability and fear. This hypothesis will be tested in 2 aims. Aim 1 will determine if SFO►IL PFC projections regulate compromised fear extinction and IL neuronal excitability in mice with HDM-induced mixed Th2/Th17 inflammation. Using a retroCre- dependent chemogenetic strategy, we will inhibit or activate SFO►IL projections to assess effects on fear extinction in mice with Th2 versus Th2/Th17 responses. AAV-ChR2 transduction of SFO neurons and patch- clamp recordings in IL neurons will be undertaken. Aim 2 will determine if microglial IL-17RA signaling in the SFO drives HDM-induced fear extinction deficits. Using SFO targeted cell-specific AAV-Cre in Il17rafl/fl mice, we will assess the necessity of IL17RA signaling in HDM-induced extinction deficits. The transcriptional profile of SFO-derived microglia and non-microglial cells will be generated for cell-type specific gene expression signatures to identify DEGs and downstream signaling pathways in Th2/Th17 mice. Finally, the impact of IL-17A on IL-projecting SFO neurons will be assessed using patch-clamp electrophysiology in slices of brains Th2/Th17 mice, +/- targeted microglial IL-17RA ablation, inhibition of previously identified modulators of SFO microglia- neuron signaling and other transcriptomic-identified targets. Impact: Our studies will inform on how adaptive immune mediators modulate brain function and behavior and identify novel risk factors and therapeutic targets for fear-associated pathologies. Beyond asthma, our findings have implications for other conditions where IL- 17A is elevated in response to pulmonary pathologies (e.g. bacterial pneumonia, ARDS, COVID-19).
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).